TP53 and neoplasm: A number of biomarkers have been proposed to assess immune responses in cancer therapy,(10) including p53 mutations,(11) total lymphocyte counts,(12,13) markers for DNA repair,(14) tumor neoantigens,(2,15) tumor infiltrating lymphocytes,(16–18) myeloid-derived suppressor cells (MDSCs),(19) and signaling molecules like damage-associated molecular patterns (DAMPs) and cytokines.(20) Despite their potential utility, each of these biomarkers faces significant methodological and practical limitations that restrict their reliability and clinical applicability.